Breaking News Instant updates and real-time market news.

VRTX

Vertex

$152.01

-0.95 (-0.62%)

, GLPG

Galapagos NV

$115.19

6.36 (5.84%)

07:12
02/13/18
02/13
07:12
02/13/18
07:12

Vertex halted trials in France as protest, says H.C. Wainwright

H.C. Wainwright analyst Andrew Fein says he learned via Twitter and a news article that Vertex Pharmaceuticals (VRTX) decided to discontinue the Phase 3 trials of its triple combination therapy for cystic fibrosis in France due to an inability to reach reimbursement agreement with the French authorities for Orkambi. Releasing patients may inadvertently help Vertex's competitors gain ground, especially Galapagos (GLPG) and Proteostasis (PTI), Fein tells investors in a research note. He keeps a Neutral rating on Vertex shares with a $103 price target.

VRTX

Vertex

$152.01

-0.95 (-0.62%)

GLPG

Galapagos NV

$115.19

6.36 (5.84%)

PTI

Proteostasis

$3.01

0.27 (9.85%)

  • 28

    Feb

VRTX Vertex
$152.01

-0.95 (-0.62%)

02/01/18
LEER
02/01/18
NO CHANGE
Target $190
LEER
Outperform
Vertex price target raised to $190 from $175 at Leerink
Leerink analyst Geoffrey Porges raised his price target for Vertex to $190 from $175 saying "strong" Q4 and triple data offer upside. The analyst reiterates an Outperform rating on the shares.
02/01/18
RBCM
02/01/18
NO CHANGE
Target $200
RBCM
Outperform
Vertex price target raised to $200 from $181 at RBC Capital
RBC Capital RBC Capital analyst Brian Abrahams raised his price target on Vertex to $200 and kept his Outperform rating, saying that Q4 earnings highlighted continued opportunity in the CF market. The analyst adds that the "best-case data from two next-gen correctors show activity even better than game-changing results from first two", setting the stage for pivotal trial starts.
02/01/18
DBAB
02/01/18
NO CHANGE
Target $193
DBAB
Buy
Vertex investors should pay more attention to Galapagos, says Deutsche Bank
Deutsche Bank analyst Navin Jacob raised his price target for Vertex Pharmaceuticals (VRTX) to $193 from $175 following last night's Q4 results and keeps a Buy rating on the shares. The triple efficacy data are better than expected, and create a "very high hurdle" for competitors, Jacob tells investors in a research note. He believes, however, that Vertex investors should be paying more attention to Galapagos NV (GLPG). Galapagos CEO Ono van de Stolpe has "100% confidence" that the company will be getting its first novel triple combo into patients in Q1, Jacob tells investors in a research note after meeting with the executive. The analyst expects some volatility to Vertex shares if Galapagos is able to start the triple trial in Q1. Jacob, however, adds that his math puts Galapagos two-and-a-half years behind Vertex and that the efficacy hurdle is "VERY high."
02/01/18
JEFF
02/01/18
NO CHANGE
Target $195
JEFF
Buy
Jefferies sees Vertex moving higher, ups target to $195
Jefferies analyst Michael Yee raised his price target for Vertex Pharmaceuticals to $195 from $185 and reiterates a Buy rating on the shares following last night's Q4 results. The company's triple pill could triple earnings in the next five years with no biosimilar or generic issues on the horizon, Yee tells investors in a research note. He sees the stock moving higher.
GLPG Galapagos NV
$115.19

6.36 (5.84%)

01/03/18
JEFF
01/03/18
NO CHANGE
Target $185
JEFF
Buy
Vertex competitor's cystic fibrosis update unsurprising, says Jefferies
Jefferies analyst Michael Yee says last night's cystic fibrosis update from Vertex Pharmaceuticals (VRTX) competitor Galapagos NV (GLPG) contained no surprises. None of Galapagos' developments are unexpected, and 2018 remains a period where the Vertex competitor is running a number of "proof of concept" studies to see if it has something, Yee tells investors in a research note. He believes challenges remain for cystic fibrosis competitors because making a triple requires three individual drugs to show minimal drug-drug interactions and have a clean side effect profile. Yee keeps a Buy rating on Vertex with a $185 price target.
09/15/17
STFL
09/15/17
NO CHANGE
Target $120
STFL
Buy
Galapagos NV price target raised to $120 from $101 at Stifel
After hosting a call with two key opinion leaders on idiopathic pulmonary fibrosis, Stifel analyst Adam Walsh noted that the physicians expressed the view that the efficacy of GLPG1690 in the Phase 2 FLORA trial "was as good as one could have hoped for." As a result of the positive physician feedback, he increased his probability of success for '1690 to 15% from 10% and raised his price target on Galapagos to $120 from $101. Walsh keeps a Buy rating on Galapagos shares.
09/14/17
RBCM
09/14/17
INITIATION
Target $98
RBCM
Sector Perform
Galapagos NV initiated with a Sector Perform at RBC Capital
RBC Capital analyst Brian Abrahams started Galapagos NV with a Sector Perform rating and $98 price target.
PTI Proteostasis
$3.01

0.27 (9.85%)

12/12/17
LEER
12/12/17
NO CHANGE
Target $8
LEER
Proteostasis price target raised to $8 from $6 at Leerink
12/12/17
JMPS
12/12/17
NO CHANGE
Target $200
JMPS
Outperform
Proteostasis data not as positive as Vertex, says JMP Securities
JMP Securities analyst Liisa Bayko says Proteostasis Therapeutics' (PTI) CF programs look positive, but not as positive as Vertex (VRTX) at this point. Nonetheless, the analyst acknowledges that it remains early days for Proteostasis and she still needs to see how its internal triple combination will perform. Bayko reiterates an Outperform rating and $200 price target on Vertex shares.
12/12/17
BARD
12/12/17
NO CHANGE
Target $25
BARD
Outperform
Proteostasis price target nearly doubled to $25 at Baird
Baird analyst Brian Skorney noted that Proteostasis (PTI) reported proof-of-concept data for the company's lead drug, PTI-428, that surpassed his expectations and "clearly confirms" that PTI-428 is biologically active. Though not "as mind-blowing as Vertex's triple data," he would argue that the benefit should be taken at face value and that PTI-428 is a first-in-class "amplifier," Skorney tells investors. The analyst raised his price target on Proteostasis to $25 from $13 on his view of the increased probability of success for PTI-428. Proteostasis Therapeutics shares are up 78% in pre-market trading to $4.19.
08/16/17
LEER
08/16/17
NO CHANGE
Target $9
LEER
Outperform
Proteostasis price target lowered to $9 from $17 at Leerink
Leerink analyst Joseph Schwartz lowered his price target for Proteostasis to $9 from $17 but reiterated an Outperform rating on the shares. The analyst notes that competitive developments have raised investor concern about the future of Proteostasis, but believes the company's current market cap of about $60M reflects a worst case scenario that assigns very little if any credit to the company's technology ahead of potentially impactful data in 2H17 and beyond.

TODAY'S FREE FLY STORIES

FIT

Fitbit

$5.93

0.22 (3.86%)

15:00
08/20/18
08/20
15:00
08/20/18
15:00
Options
Fitbit calls active as shares extend gains »

Fitbit calls active as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

MMM

3M

$204.54

-0.27 (-0.13%)

, SGMS

Scientific Games

$30.45

0.85 (2.87%)

14:53
08/20/18
08/20
14:53
08/20/18
14:53
Hot Stocks
3M announces filing of touch screen technology patent infringement lawsuit »

3M (MMM) and 3M…

MMM

3M

$204.54

-0.27 (-0.13%)

SGMS

Scientific Games

$30.45

0.85 (2.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BPY

Brookfield Property

$19.94

-0.15 (-0.75%)

14:49
08/20/18
08/20
14:49
08/20/18
14:49
Conference/Events
Brookfield Property management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

LCI

Lannett

$5.40

-8.1 (-60.00%)

14:49
08/20/18
08/20
14:49
08/20/18
14:49
Downgrade
Lannett rating change  »

Lannett downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 28

    Aug

AABA

Altaba

$69.92

1.74 (2.55%)

14:49
08/20/18
08/20
14:49
08/20/18
14:49
Options
Altaba Inc options imply 7.0% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SUM

Summit Materials

$20.26

0.31 (1.55%)

14:47
08/20/18
08/20
14:47
08/20/18
14:47
Conference/Events
Summit Materials management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 22

    Aug

  • 23

    Aug

  • 10

    Sep

CAPL

CrossAmerica

$18.15

0.15 (0.83%)

, ANDV

Andeavor

$147.76

2.82 (1.95%)

14:46
08/20/18
08/20
14:46
08/20/18
14:46
Hot Stocks
FTC approves Alimentation Couche-Tard sale of two Minnesota fuel stations »

The Federal Trade…

CAPL

CrossAmerica

$18.15

0.15 (0.83%)

ANDV

Andeavor

$147.76

2.82 (1.95%)

ANCUF

Alimentation Couche-Tard

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GME

GameStop

$15.94

0.61 (3.98%)

14:45
08/20/18
08/20
14:45
08/20/18
14:45
Options
GameStop call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PHII

PHI, Inc

$8.59

0.09 (1.06%)

14:45
08/20/18
08/20
14:45
08/20/18
14:45
Hot Stocks
Alesia Value fund reports 4.7% stake in PHI »

On August 20,Alesia…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$216.05

-1.6 (-0.74%)

14:41
08/20/18
08/20
14:41
08/20/18
14:41
Periodicals
Breaking Periodicals news story on Apple »

Apple planning revamped…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCHVF

MGM China

$0.00

(0.00%)

14:36
08/20/18
08/20
14:36
08/20/18
14:36
Upgrade
MGM China rating change  »

MGM China upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:35
08/20/18
08/20
14:35
08/20/18
14:35
General news
The Fed has become an unexpected focus »

The Fed has become an…

14:35
08/20/18
08/20
14:35
08/20/18
14:35
General news
Canada wholesale preview »

Canada wholesale preview:…

CTWS

Connecticut Water

$69.10

0.1 (0.14%)

14:34
08/20/18
08/20
14:34
08/20/18
14:34
Hot Stocks
PURA approves rate settlement agreement for Connecticut Water »

Connecticut Water Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMB

Williams

$30.38

-0.095 (-0.31%)

14:30
08/20/18
08/20
14:30
08/20/18
14:30
Conference/Events
Williams management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 22

    Aug

AMZN

Amazon.com

$1,880.70

-1.24 (-0.07%)

14:29
08/20/18
08/20
14:29
08/20/18
14:29
Periodicals
Amazon hires well-known cardiologist amid push into health, CNBC says »

Amazon has hired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Sep

AMCX

AMC Networks

$61.70

1.28 (2.12%)

14:25
08/20/18
08/20
14:25
08/20/18
14:25
Conference/Events
AMC Networks management to meet with RBC Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 22

    Aug

  • 23

    Aug

OSPR

Osprey Energy Acquisition

$11.27

0.065 (0.58%)

14:25
08/20/18
08/20
14:25
08/20/18
14:25
Conference/Events
Osprey Energy Acquisition to host special shareholder meeting »

Special shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

PPG

PPG

$109.64

1.23 (1.13%)

14:24
08/20/18
08/20
14:24
08/20/18
14:24
Conference/Events
PPG management to meet with UBS »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 05

    Sep

NFLX

Netflix

$330.55

13.77 (4.35%)

14:21
08/20/18
08/20
14:21
08/20/18
14:21
Technical Analysis
Technical Take: Netflix may test downtrend resistance line »

The shares are up over…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
08/20/18
08/20
14:17
08/20/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
08/20/18
08/20
14:16
08/20/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LCI

Lannett

$5.35

-8.15 (-60.37%)

14:16
08/20/18
08/20
14:16
08/20/18
14:16
Downgrade
Lannett rating change  »

Lannett downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 28

    Aug

MBI

MBIA

$10.78

-0.22 (-2.00%)

14:15
08/20/18
08/20
14:15
08/20/18
14:15
Options
MBIA put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAC

Bank of America

$30.79

0.05 (0.16%)

14:08
08/20/18
08/20
14:08
08/20/18
14:08
Hot Stocks
SEC says Merrill Lynch to pay $8.9M to settle charges of undisclosed conflict »

The Securities and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.